Institute for Safe Medication Practices Lifetime Achievement Award 2011.

Lawrence A. Trissel was awarded the 2011 Institute for Safe Medication Practices Lifetime Achievement Award. In this article, the author acknowledges his appreciation of being selected for this award, pays his respects to those who honored him, and discusses the future of pharmacy as it relates to drug stability and compatibility efforts.

Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.

Purpose: The physical compatibility of ceftaroline fosamil with commonly used medications and diluents (a total of 73 drugs in 219 admixtures) during simulated Y-site administration was evaluated.

Methods: Duplicate 5-mL samples of ceftaroline fosamil (2.22 mg/mL) in 5% dextrose injection, 0.

Drug Compatibility with a New Generation of VISIV Polyolefin Infusion Solution Containers.

A new generation of VISIV polyolefin intravenous solution containers, made of a new and different proprietary polymer, were evaluated for sorption and leaching potential with a cadre of drugs known to exhibit those phenomena with polyvinylchloride containers. Sorption potential was evaluated for amiodarone hydrochloride, carmustine, regular human insulin, lorazepam, nitroglycerin, sufentanil citrate, and thiopental sodium. Leaching potential was evaluated for tacrolimus and teniposide as well as the vehicles of docetaxel and paclitaxel.

Compatibility and stability of palonosetron hydrochloride and propofol during simulated y-site administration.

Palonosetron hydrochloride is a longer-acting, selective 5-HT3 receptor antagonist that has been approved for prevention of chemotherapy-induced nausea and vomiting and is being evaluated for prevention of postoperative nause and vomiting. The objective of this study was to evaluate the physical and chemical stablity of palonosetron hydrochloride 50 mcg/mL when mixed with undiluted propofol 1% during simulated Y-site administation. Duplicate samples of this mixture were tested.

Quality-control analytical methods: overview of beyond-use dating for compounded sterile preparations.

United States Pharmacopeia Chapter 797 provides guidelines and standards that deal with the preparation, compounding, and labeling of compounded sterile preparations. These standards ensure patient care and safety by defining safe practice. The Chapter gives instructions on determining beyond-use dates for the different risk categories associated with compounded preparations.

Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.

Purpose: The physical and chemical compatibility of palonosetron hydrochloride with atropine sulfate, famotidine, heparin sodium, lidocaine hydrochloride, and potassium chloride during simulated Y-site administration were studied.

Methods: Test samples were prepared in duplicate by separately mixing 7.5-mL samples of undiluted palonosetron hydrochloride 50 microg/mL with 7.

Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration.

Palonosetron hydrochloride is a longer-acting, selective 5-HT3 receptor antagonist that has been approved for the prevention of chemotherapy-induced nausea and vomiting ad is being evaluated for the prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50mcg/mL when mixed with Lactated Ringer's injection, 6% hetastarch in lactated electrolyte injection, or 15% mannitol injection during simulated Y-site administration. Duplicate samples of each admixture were tested.

Physical and chemical stability of esomeprazole sodium solutions.

Background: Esomeprazole sodium (Nexium IV, AstraZeneca) is the S-isomer of omeprazole and acts as a proton pump inhibitor gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis. Currently, there is no information on the long-term stability of esomeprazole sodium in infusion solutions beyond 12 hours.

Objective: To evaluate the stability of esomeprazole sodium in 5% dextrose, 0.

Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated y-site administration.

The objective of this study was to evaluate the physical and chemical stability of undiluted palonosetron hydrochloride 50 mcg/mL when mixed with undiluted glycopyrrolate 0.2 mg/mL and neostigmine methylsulfate 0.5 mg/mL during simulated Y-site administration.

Compatibility of doripenem with other drugs during simulated Y-site administration.

Purpose: The compatibility of doripenem diluted for infusion with 82 other drugs during simulated Y-site administration was studied.

Methods: Five-milliliter samples of doripenem 5 mg/mL in 5% dextrose injection and separately in 0.9% sodium chloride injection were combined with 5 mL of 82 other drugs, undiluted or diluted in 5% dextrose injection or 0.

Compatibility of caspofungin acetate injection with other drugs simulated y-site coadministration.

The physical compatibility of caspofungin acetate injection with selected other drugs during simulated Y-site coadministration was evaluated by visual observation and turbidity measurement. Five-milliliter samples of caspofungin acetate 0.7 mg/mL in 0.

Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated y-site administration.

Palonosetron hydrochloride is a relatively long-acting selective 5-HT3 receptor antagonist that has been approved for the prevention of chemotherapy-induced nausea and vomiting and is being evaluated for the prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50 mcg/mL when mixed with gentamicin sulfate 5 mg/mL, metronidazole 5 mg/mL, or vancomycin hydrochloride 5 mg/mL during simulated Y-site administration. Duplicate samples of palonosetron hydrochloride with each of the anti-infectives were tested.

Compatibility and stability of palonosetron hydrochloride with four neruomuscular blocking agents during simulated y-site administration.

Palonosetron hydrochloride is a longer-acting selective 5-HT3 receptor antagonist that has been approved for the prevention of chemotherapy-induced nausea and vomiting and is being evaluated for the prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50 mcg/mL when mixed with any of the neuromuscular blocking drugs cisatracurium besylate 0.5 mg/mL, rocuronium bromide 1 mg/mL, succinylcholine chloride 2 mg/mL, and vecuronium bromide 1 mg/mL during simulated Y-site administration.

Palonosetron hydrochloride compatiblity and stability with three B-lactam anitbiotic during simulated y-site adminstration.

Palonosetron hydrochloride is a relatively long-acting selective 5-HT3 receptor antagonist that has been approved for the prevention of chemotherapy-induced nausea and vomiting and is being ealuated for the prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50 mcg/mL with the B-lactam antibiotics cefazolin sodium 20 mg/mL, cefotetan disodium 20 mg/mL, and the combination ampicillin sodium-sulbactam sodium 20 mg/mL and 10 mg/mL, respectively, during simulated Y-site administration. The effects of each of the antibiotics on palonosetron hydrochloride in these admixtures were tested in triplicate.

Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.

Purpose: The physical and chemical compatibility of palonosetron hydrochloride with fentanyl citrate, hydromorphone hydrochloride, meperidine hydrochloride, morphine sulfate, and sufentanil citrate during simulated Y-site administration was studied.

Methods: Test samples were prepared in triplicate by mixing 7.5-mL samples of undiluted palonosetron 50 microg/mL (of palonosetron) with 7.

Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.

Purpose: Using a multiple-step testing medium-risk-level compounding test procedure, the evaluation of two work-practice changes to determine if the changes could effectively reduce the potential for contamination occurrence was conducted.

Summary: Along with training and evaluation of aseptic sterile compounding techniques, each individual pharmacist and pharmacy technician at M. D.

Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated y-site administration.

The objective of this study was to evaluate the physical and chemical stability of mixtures of undiluted palonosetron hydrochloride 50 micrograms/mL with undiluted metoclopramide hydrochloride 5 mg/mL and with promethazine hydrochloride 2 mg/mL diluted in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 7.5 mL of palonosetron hydrochloride with 7.

Drug compatibility with new polyolefin infusion solution containers.

Purpose: The compatibility of new polyolefin (VISIV) containers with seven drugs that have exhibited sorption to polyvinyl chloride (PVC) containers and sets and an additional four drugs that have exhibited leaching of plasticizer or other polymer matrix components from PVC containers and sets was studied.

Methods: For the sorption portion of the study, amiodarone hydrochloride, carmustine, regular human insulin, lorazepam, nitroglycerin, sufentanil citrate, and thiopental sodium and their respective reference standards were used. For the leaching portion of the study, docetaxel, paclitaxel, tacrolimus, teniposide, and diethylhexyl phthalate (DEHP) reference standard, were used.

Temozolomide stability in extemporaneously compounded oral suspensions.

Temozolomide, commercially available in capsules, is an oral alkylating agent used to treat brain tumors. The purpose of this study was to determine the pharmaceutical acceptability and chemical stability of temozolomide in two extemporaneously compounded suspension formulations prepared from the capsules. The temozolomide oral suspensions were prepared from 100-mg commercial capsules yielding a nominal temozolomide concentration of 10 mg/mL.

Physical instability of frozen pemetrexed solutions in PVC bags.

Background: Pemetrexed is a multitargeted antifolate antineoplastic agent indicated for single-agent use in advanced or metastatic non-small-cell lung cancer and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery. Currently, there is no information on the stability of frozen pemetrexed solutions.

Objective: To evaluate the stability of pemetrexed admixtures in common infusion solutions frozen at -20 degrees C to determine the drug stability period up to 90 days.

Physical and chemical stability of pemetrexed in infusion solutions.

Background: Pemetrexed is a multitargeted, antifolate, antineoplastic agent that is indicated for single-agent use in locally advanced or metastatic non-small-cell lung cancer after prior chemotherapy and in combination with cisplatin for the treatment of malignant pleural mesothelioma not treatable by surgery. Currently, there is no information on the long-term stability of pemetrexed beyond 24 hours.

Objective: To evaluate the longer-term physical and chemical stability of pemetrexed 2, 10, and 20 mg/mL in polyvinyl chloride (PVC) bags of dextrose 5% injection and NaCl 0.

Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration.

The objective of this study was to evaluate the physical and chemical stability of mixtures of undiluted palonosetron hydrochloride 50 micrograms/mL with dacarbazine 4 mg/mL and with methylprednisolone sodium succinate 5 mg/mL in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 7.5 mL of palonosetron hydrochloride with 7.

Compatibility of micafungin injection with other drugs during simulated y-site co-administration.

The objective of this study was to evaluate the physical compatibility of micafungin injection with selected other drugs during simulated Y-site co-administration. Physical stability was assessed by both visual observation and turbidity measurement. Micafungin in 0.

Quality-Control Analytical Methods: Particulate Matter In Injections: What is It and What are the Concerns?

The presence of particulate matter in intravenous injections, especially in large numbers, represents a potentially life-threatening health hazard. The United States Pharmacopeia has established procedures and standards to ensure the quallity of intravenous injections, including particulate counts. Compounding pharmacists can reduce the incidence of adverse events in patients by assuring the quality of their preparations through filtration of intravenous preparations and analytical testing procedures.